Corvus Pharmaceuticals
CRVS
10.41
-0.15
-1.42%
Corvus Pharmaceuticals
US · CRVS
#3339 by market cap
Listed 2016
10.41
-0.15
-1.42%
Live - 5344 symbols - heartbeat 468s ago
· 2026-10-08 08:12
Pre-market
10.13
-2.69%
After-hours
10.52
+1.06%
- Market cap
- 875.70M
- P/E (TTM)i
- -16.27
- P/Bi
- 3.89
- EPSi
- -0.53
- Div yieldi
- 0.00%
- 52W posi
- 20%
Reader sentiment
Are you bullish or bearish on CRVS?
Anonymous reader poll. Unscientific, not investment advice.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.
- Founded
- 2014
- CEO
- Dr. Richard A. Miller,M.D.
- Employees
- 37
- Headquarters
- South San Francisco, California, United States of America
- Fiscal year end
- 12-31
- Website
- corvuspharma.com
Company profile
- Exchange
- US
- Symbol
- CRVS
- Market-cap rank
- #3339
- Listing date
- 2016-03-23
- Market cap
- 875.70M
- Float cap
- 757.73M
- Shares out
- 84.12M
- Float shares
- 72.79M
Sectors & themes
Quote time 2026-10-08 08:12:11 · For reference only, not investment advice and not tailored to your situation.